Tandem Diabetes Care reports Q2 2022 earnings; specific figures not in filing text

TANDEM DIABETES CARE INC

2022-Q2 EPS reported -$0.47 revenue$376,169,000

Press release for Q2 ended June 30, 2022 furnished as Exhibit 99.1 but not reproduced in provided text.
No financial results (revenue, EPS, guidance) are available from the 8-K body alone.
Filing is standard Item 2.02 disclosure; actual data requires reviewing the attached exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.